Numajiri Maki, Aoki Jun, Iwahashi Kazuhiko, Fukamauchi Fumihiko, Enomoto Minoru, Yoshihara Eiji, Murayama Ohshi, Nishizawa Daisuke, Ikeda Kazutaka, Ishigooka Jun
Neurophysiology, Graduate School of Environmental Health Sciences, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara 252-5201, Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Jun;32(3):161-3.
GSK-3beta codes for an enzyme which is a target for the action of mood stabilizers, lithium and possibly of valproic acid. The relationship between the polymorphisms (SNPs) of GSK-3beta-50T/C and -1727A/T and the effect of lithium was studied among 29 Japanese bipolar patients. It was shown that GSK-3beta-50T/C may be linked with the effect of lithium treatment. There is a significantly higher T-allele frequency in the lithium responders than non-responders (df = 1, chi2 = 6.971, 0.01 > P > 0.001; Yates' continuity correction). However, there is not a significant relationship between the polymorphisms of GSK-3beta-1727A/T and the effect of lithium treatment.
GSK - 3β编码一种酶,该酶是心境稳定剂锂以及可能还有丙戊酸作用的靶点。在29名日本双相情感障碍患者中研究了GSK - 3β - 50T/C和 - 1727A/T的多态性(单核苷酸多态性,SNPs)与锂效应之间的关系。结果表明,GSK - 3β - 50T/C可能与锂治疗的效果有关。锂反应者中的T等位基因频率显著高于无反应者(自由度 = 1,卡方 = 6.971,0.01 > P > 0.001;采用耶茨连续性校正)。然而,GSK - 3β - 1727A/T的多态性与锂治疗效果之间没有显著关系。